| Overview |
| bs-1468R-FITC |
| MDR1 Polyclonal Antibody, FITC Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MDR1 |
| 1051-1280/1280 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5243 |
| Cell membrane |
| P-Glycoprotein; Multi Drug Resistance Associated Protein, ABCB1; ATP-binding cassette sub-family B MDR/TAP, member 1; ABC20; CD243; CD243 antigen; CLCS; Multidrug resistance protein 1; P glycoprotein 1; p-GP; gp170; P gp; PGY1. |
| P Glycoprotein, the product of the MDR1 gene, is expressed in distinct non-malignant cells, typically cells with secretory and excretory functions. It is assumed to function as an ATP-dependent drug efflux pump with broad substrate specificity. The highest expression of P Glycoprotein has been observed in kidney (proximal tubules), liver (bile canaliculi), adrenal gland and intestine, suggesting that the primary role of P Glycoprotein is in the normal secretion of physiological metabolites and ingested chemicals into bile, urine and the lumen of the intestinal tract. Elevated levels of P Glycoprotein have also been reported in multidrug-resistant cell lines and in colon, endometrial, ovarian, and breast tumors, as well as in sarcomas and leukemias / lymphomas. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz